A rational approach to select immunogenic peptides that induce IFN-γ response against Toxoplasma gondii in human leukocytes

Immunobiology

Volumn 220, Issue 12, 2015, Pages 1337-1342

  Cardona, Néstor I ^a   Moncada, Diego M ^a   Gómez Marin, Jorge E ^a  

^a UNIVERSIDAD DEL QUINDÍO   (Colombia)

Author keywords

ELISPOT; Immunoinformatics; Interferon gamma; Peptides; Vaccine

Indexed keywords

GAMMA INTERFERON; HLA A ANTIGEN; EPITOPE; HLA A2 ANTIGEN; PEPTIDE;

AMINO ACID SEQUENCE; ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; HAPLOTYPE; HUMAN; HUMAN CELL; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN INTERACTION; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; TOXOPLASMA GONDII; TOXOPLASMOSIS; VALIDITY; BIOLOGY; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; PARASITOLOGY; POSITION WEIGHT MATRIX; PROCEDURES; PROTEIN CONFORMATION; PROTEIN MOTIF; TOXOPLASMA;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; COMPUTATIONAL BIOLOGY; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY TESTING; HLA-A2 ANTIGEN; HUMANS; INTERFERON-GAMMA; LEUKOCYTES; LEUKOCYTES, MONONUCLEAR; MODELS, MOLECULAR; PEPTIDES; POSITION-SPECIFIC SCORING MATRICES; PROTEIN CONFORMATION; TOXOPLASMA; TOXOPLASMOSIS;

EID: 84942825095     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2015.07.009     Document Type: Article

References (33)

1. Blanchard N., Gonzalez F., Schaeffer M., Joncker N.T., Cheng T., Shastri A.J., et al. Immunodominant, protective response to the parasite Toxoplasma gondii requires antigen processing in the endoplasmic reticulum. Nature Immunol. 2008, 9:937-944.
2. Calis J.J.A., Maybeno M., Greenbaum J.A., Weiskopf D., De Silva A.D., Sette A., et al. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput. Biol. 2013, 9:E1003266.
3. Cardona N., Basto N., Parra B., Zea A.F., Pardo C.A., Bonelo A., Gomez-Marin J.E. Detection of Toxoplasma DNA in the peripheral blood of HIV-positive patients with neuropportunistic infections by a real time PCR assay. J. Neuroparasitol. 2011, 2:6. Article ID N110402. 10.4303/jnp/N110402.
4. Cesbron-Delauw M.F., Capron A. Excreted/secreted antigens of Toxoplasma Gondii - their origin and role in the host-parasite interaction. Res. Immunol. 1993, 144:41-44.
5. Cong H., Mui E.J., Witola W.H., Sidney J., et al. Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T Cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8 T Cell epitope based adjuvanted vaccine protective against Toxoplasma gondii. Immunome Res. 2010, 6:12. 10.1186/1745-7580-6-12.
6. Cong H., Mui E.J., Witola W.H., Sidney J., Alexander J., Sette A., Maewal A., Mcleod R. Towards an immunosense vaccine to prevent Toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201. Vaccine 2011, 29:754-762. 10.1016/j.vaccine.2010.11.015.
7. Cong H., Mui E.J., Witola W.H., Sidney J., Alexander J., Sette A., et al. Toxoplasma gondii HLA-B*0702-restricted GRA7(20-28) peptide with adjuvants and a universal helper T cell epitope elicits CD8(+) T cells producing interferon-gamma and reduces parasite burden in HLA-B*0702 mice. Human Immunol. 2012, 73:1-10. 10.1016/j.humimm.2011.10.006.
8. Crooks G.E. WebLogo. A sequence logo generator. Genome Res. 2004, 14:1188-1190.
9. Edgar R.C. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004, 32:1792-1797.
10. Engelhard V.H. Structure of peptides associated with class I and class II MHC molecules. Ann. Rev. Immunol. 1994, 12:181-207.
11. Gómez-Marin J.E., de-la-Torre A., Angel-Muller E., Rubio J., Arenas J., Osorio E., et al. First Colombian multicentric newborn screening for congenital toxoplasmosis. PLoS Negl. Trop. Dis. 2011, 5(5):e1195.
12. Gajria B., Bahl A., Brestelli J., Dommer J., Fischer S., Gao X., et al. ToxoDB: an integrated Toxoplasma gondii database resource. Nucleic Acids Res. 2007, 36:D553-D556.
13. Goodswen S.J., Kennedy Ellis P.J.J.T. A guide to in silico vaccine discovery for eukaryotic pathogens. Briefings Bioinf. 2013, 14:753-774. 10.1093/bib/bbs066.
14. Goodswen S.J., Kennedy P.J., Ellis J.T. Vacceed: a high-throughput in silico vaccine candidate discovery pipeline for eukaryotic pathogens based on reverse vaccinology. Bioinformatics 2014, 30:2381-2383. 10.1093/bioinformatics/btu300.2381-3.
15. Goodswen S.J., Kennedy P.J., Ellis J.T. A novel strategy for classifying the output from an in silico vaccine discovery pipeline for eukaryotic pathogens using machine learning algorithms. BMC Bioinf. 2013, 14:31. 10.1186/1471-2105-14-315.
16. Henriquez F.L., Woods S., Cong H., Mcleod R., Roberts C.W. Immunogenetics of Toxoplasma gondii informs vaccine design. Trends Parasitol. 2010, 26:550-555. 10.1016/j.pt.2010.06.004.
17. Holzhütter H.G., Kloetzel P.M. A kinetic model of vertebrate 20s proteasome accounting for the generation of major proteolytic fragments from oligomeric peptide substrates. Biophys. J. 2000, 79:1196-1205.
18. Holzhütter H.G., Frömmel C., Kloetzel P.M. A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20s proteasome. J. Mol. Biol. 1999, 286:1251-1265.
19. Karosiene E., Lundegaard C., Lund O., Morten N. NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics 2012, 64:177-186.
20. Kumar N., Mohanty D. MODPROPEP: a program for knowledge-based modeling of protein-peptide complexes. Nucleic Acids Res. 2007, 35:W549-W555.
21. Liang B., Zhu L., Liang Z., Weng X., Lu X., Zhang C., Li H., Wu X. A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China. Cell. Mol. Immunol. 2006, 3:453-458.
22. Mendes E.A., Fonseca F.G., Casério B.M., Colina J.P., Gazzinelli R.T., Caetano B.C. Recombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1. PLoS One 2013, 8(5):e63201.
23. Pettersen E.F., Goddard T.D., Huang C.D., Couch G.S., Greenblatt D.M., Meng E., Ferrin T. UCSF chimera: a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25:1605-1612.
24. Pfaff A., de-la-Torre A., Rochet E., Brunet J., Sabou M., Sauer A., et al. New clinical and experimental insights into old world and neotropical ocular toxoplasmosis. Int. J. Parasitol. 2014, 44:99-107. 10.1016/j.ijpara.2013.09.007.
25. Qu D., Han J., Du A. Evaluation of protective effect of multiantigenic DNA vaccine encoding MIC3 and ROP18 antigen segments of Toxoplasma gondii in mice. Parasitol. Res. 2013, 112:2593-2599.
26. Rappuoli R. Reverse vaccinology. Curr. Opin. Microbiol. 2000, 3:445-450.
27. Robertson L.J., van der Giessen J.W., Batz M.B., Kojima M., Cahill S. Have foodborne parasites finally become a global concern. Trends Parasitol. 2013, 29:101-103.
28. Schneider C.A., Rasband W.S., Eliceiri W.K. NIH image to imageJ: 25 Years of image analysis. Nat. Methods 2012, 9:671-675.
29. Siachoque H., Guzman F., Burgos J., Patarroyo M.E., Gomez-Marin J.E. Toxoplasma gondii: immunogenicity and protection by P30 peptides in a murine model. Exp. Parasitol. 2006, 114:62-65.
30. Tan T.G., Mui E., Cong H., Witola W.H., Montpetit A., Muench S.P., et al. Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine 2010, 28:3977-3989.
31. Tao Q., Fang R., Zhang W., Wang Y., Cheng J., Li Y., Fang K., et al. Protective immunity induced by a DNA vaccine-encoding Toxoplasma gondii microneme protein 11 against acute toxoplasmosis in BALB/c mice. Parasitol. Res. 2013, 112:2871-2877.
32. Vita R.L., Zarebski J.A., Greenbaum H., Emami Hoof N., Salimi R., et al. The immune epitope database 2.0. Nucleic Acids Res. 2009, 38:D854-D862.
33. Zhang N.Z., Chen J., Wang M., Petersen E., Zhu X.Q. Vaccines against Toxoplasma gondii: new developments and perspectives. Expert Rev. Vaccines 2013, 12(11):1287-1299. 10.1586/14760584.2013.844652.